Literature DB >> 8862512

Molecular oncology in pancreatic cancer.

S Gansauge1, F Gansauge, H G Beger.   

Abstract

Cancer of the pancreas still has a very poor prognosis despite improved diagnostic methods and therapeutic regimens. The reasons for the aggressiveness of this cancer are not known, and the molecular mechanisms that govern the growth of pancreatic cancer cells are still not clearly defined. During the past two decades the development of new molecular biological techniques has offered new perspectives for a better understanding of pancreatic cancer. Tumor markers such as CA19-9 and CEA are used for diagnosis and for following the postoperative course of cancer patients. Characterization of pancreatic cancer cells using several molecular biological techniques has revealed overexpression or altered expression of growth factors and adhesion molecules, implying altered cell-cell and growth-regulatory interactions. In pancreatic cancer mutations in oncogenes and tumor suppressor genes are frequently detected in p53 and K-ras. This article reviews the possible molecular approaches for diagnosis, prognosis, or even therapy of pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8862512     DOI: 10.1007/bf00207508

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  90 in total

Review 1.  Structure and function of the leukocyte adhesion molecules CD11/CD18.

Authors:  M A Arnaout
Journal:  Blood       Date:  1990-03-01       Impact factor: 22.113

2.  Production of transforming growth factor alpha in human pancreatic cancer cells: evidence for a superagonist autocrine cycle.

Authors:  J J Smith; R Derynck; M Korc
Journal:  Proc Natl Acad Sci U S A       Date:  1987-11       Impact factor: 11.205

Review 3.  Antisense of oligonucleotides and the inhibition of oncogene expression.

Authors:  J Prins; E G de Vries; N H Mulder
Journal:  Clin Oncol (R Coll Radiol)       Date:  1993       Impact factor: 4.126

Review 4.  TP53 tumor suppressor gene: a model for investigating human mutagenesis.

Authors:  C Caron de Fromentel; T Soussi
Journal:  Genes Chromosomes Cancer       Date:  1992-01       Impact factor: 5.006

5.  The A9 antigen associated with aggressive human squamous carcinoma is structurally and functionally similar to the newly defined integrin alpha 6 beta 4.

Authors:  C Van Waes; K F Kozarsky; A B Warren; L Kidd; D Paugh; M Liebert; T E Carey
Journal:  Cancer Res       Date:  1991-05-01       Impact factor: 12.701

Review 6.  Isoprenoid modification and plasma membrane association: critical factors for ras oncogenicity.

Authors:  C J Der; A D Cox
Journal:  Cancer Cells       Date:  1991-09

7.  Basic fibroblast growth factor in Dupuytren's contracture.

Authors:  A M Gonzalez; M Buscaglia; R Fox; A Isacchi; P Sarmientos; J Farris; M Ong; D Martineau; D A Lappi; A Baird
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

8.  Sensitivity and specificity of serum ribonuclease in the diagnosis of pancreatic cancer.

Authors:  A L Warshaw; K H Lee; W C Wood; A M Cohen
Journal:  Am J Surg       Date:  1980-01       Impact factor: 2.565

9.  Monoclonal antibodies and synthetic tumor-associated glycoconjugates in the study of the expression of Thomsen-Friedenreich-like and Tn-like antigens on human cancers.

Authors:  B M Longenecker; D J Willans; G D MacLean; S Selvaraj; M R Suresh; A A Noujaim
Journal:  J Natl Cancer Inst       Date:  1987-03       Impact factor: 13.506

10.  Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours.

Authors:  D E Neal; C Marsh; M K Bennett; P D Abel; R R Hall; J R Sainsbury; A L Harris
Journal:  Lancet       Date:  1985-02-16       Impact factor: 79.321

View more
  6 in total

1.  Systemic immune dysfunction in pancreatic cancer patients.

Authors:  Bertram Poch; Errki Lotspeich; Marco Ramadani; Susanne Gansauge; Hans G Beger; Frank Gansauge
Journal:  Langenbecks Arch Surg       Date:  2007-01-19       Impact factor: 3.445

2.  Differential and antagonistic effects of 9-cis-retinoic acid and vitamin D analogues on pancreatic cancer cells in vitro.

Authors:  F Pettersson; K W Colston; A G Dalgleish
Journal:  Br J Cancer       Date:  2000-07       Impact factor: 7.640

3.  Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes.

Authors:  J Däbritz; J Hänfler; R Preston; J Stieler; H Oettle
Journal:  Br J Cancer       Date:  2005-01-31       Impact factor: 7.640

Review 4.  The Potential of CAR T Cell Therapy in Pancreatic Cancer.

Authors:  Mehmet Akce; Mohammad Y Zaidi; Edmund K Waller; Bassel F El-Rayes; Gregory B Lesinski
Journal:  Front Immunol       Date:  2018-09-25       Impact factor: 7.561

Review 5.  CAR T cells in solid tumors: challenges and opportunities.

Authors:  Faroogh Marofi; Roza Motavalli; Vladimir A Safonov; Lakshmi Thangavelu; Alexei Valerievich Yumashev; Markov Alexander; Navid Shomali; Max Stanley Chartrand; Yashwant Pathak; Mostafa Jarahian; Sepideh Izadi; Ali Hassanzadeh; Naghmeh Shirafkan; Safa Tahmasebi; Farhad Motavalli Khiavi
Journal:  Stem Cell Res Ther       Date:  2021-01-25       Impact factor: 6.832

Review 6.  Chimeric Antigen Receptor T-Cells: An Overview of Concepts, Applications, Limitations, and Proposed Solutions.

Authors:  Alaa Alnefaie; Sarah Albogami; Yousif Asiri; Tanveer Ahmad; Saqer S Alotaibi; Mohammad M Al-Sanea; Hisham Althobaiti
Journal:  Front Bioeng Biotechnol       Date:  2022-06-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.